A colorectal most cancers blood check candidate from Precise Sciences fell brief in its pivotal examine, however the firm remains to be within the hunt to offer an alternative choice to the liquid biopsy that was first to market in such a most cancers and can accomplish that with assist from a competitor. Precise Sciences is buying rights to a check from Freenome that’s nearer to the market than its failed inside candidate was.
Precise Sciences is paying $75 million up entrance for U.S. rights to Freenome’s blood check. One other $700 million is tied to the achievement of milestones.
Madison, Wisconsin-based Precise Sciences is already properly established in colorectal most cancers screening with Cologuard and Cologuard Plus. Each are stool-based checks that require customers to ship a pattern to a lab for detection of most cancers DNA. Even with the market progress of those checks, the screening discipline has been pushing to broaden the non-invasive choices accessible to sufferers. The 2024 FDA approval of Guardant Well being’s Protect made that liquid biopsy the primary blood check accepted for colorectal most cancers. It’s now a part of a precision oncology testing portfolio that generated almost $688 million in gross sales final yr, in response to the corporate’s annual report.
Precise Sciences had been telling traders outcomes from a pivotal examine of its internally developed blood-based screening check could be accessible in the midst of this yr. On Aug. 6, the identical day the corporate reported second quarter 2025 monetary outcomes, the corporate disclosed outcomes that had been disappointing. The corporate mentioned outcomes confirmed sensitivities of 73% for colorectal most cancers and 14% for superior precancerous lesions at 90% specificity. Leerink Companions analyst Puneet Souda mentioned in a analysis be aware that these outcomes are beneath the 74% sensitivity mark wanted for Medicare protection, which limits its business potential.
Freenome mentioned it lately submitted to the FDA the final module of the pre-market utility for its check, which it calls SimpleScreen. The Brisbane, California-based firm plans to undergo the company a complement for its next-generation check as soon as remaining medical validation dates can be found.
The settlement give Precise Sciences unique U.S. rights to present and future variations of Freenome’s blood check for the only indication of colorectal most cancers screening. Privately held Freenome has the appropriate to incorporate colorectal most cancers screening for a multi-cancer early detection check it in growth for screening greater than 10 cancers from a single pattern of affected person blood.
Leerink’s Souda mentioned the deal is “a shot within the arm for Freenome,” offering the corporate with money and an R&D accomplice whereas nonetheless enabling it to retain multi-cancer early detection rights. However he added that Precise Sciences is unlikely to launch Freenome’s check till late 2026, following FDA approval. That retains the Wisconsin firm about two years behind Guardant Well being.
“Nonetheless, we consider (Precise Sciences’) resolution to collaborate with Freenome will assist validate their science, and is constructive for his or her different pipeline assays,” Souda mentioned.
The phrases of Precise Sciences’ cope with Freenome name for the upfront cost to be made in money by November of this yr. The milestones encompass $100 million upon first-line approval for the primary model of the check; $100 million upon first-line FDA approval for the next-generation check contingent on hitting specified efficiency benchmarks; and $500 million if rated as a first-line A or B check in the US Preventive Companies Taskforce (USPSTF) tips or if it meets sure payer contracted protection necessities.
Royalties as a consequence of Freenome will vary from 0% to 10%, relying on the check’s profitability and provisions that cut back the royalty burden so it doesn’t make commercialization unprofitable. If sure unspecified standards are usually not met, the settlement offers Precise Sciences the appropriate to terminate the deal. Precise Sciences has additionally dedicated $20 million over the subsequent three years in joint R&D bills leveraging the Freenome expertise.
Picture: harmpeti, Getty Photographs
